

Statistical Considerations for Utilizing Fit-for-Use Real-World Data in Drug Development to Inform Regulatory Decision Making

Behoz Shang*

Department of Biometrics, University of Texas, Texas, USA

Introduction

Utilizing fit-for-use Real-World Data (RWD) in drug development to inform regulatory decision making is an increasingly important area in pharmaceutical research. Real-world data refers to data collected outside of traditional clinical trial settings and can come from various sources, such as electronic health records, claims databases, patient registries, and wearable devices. Integrating RWD into drug development and regulatory decision making can offer valuable insights into a drug's safety, effectiveness, and real-world performance. Ensuring the quality and completeness of the real-world data is crucial. Biometric systems provide a more robust solution by linking an individual's unique biometric traits to their identity [1].

Description

Statistical methods should be employed to assess data integrity, identify missing data, and address any potential biases or confounding factors. Data quality assessments should be conducted early in the process to determine if the available data is fit-for-use for the specific regulatory question. Real-world data often come from diverse sources and may require standardization to facilitate comparability and integration across different datasets. Standardizing variables and data formats can help ensure consistency in the analysis. Rigorous study design and appropriate statistical analysis methods are essential when using real-world data to support regulatory decisions. Observational studies using real-world data are prone to selection biases and confounding. Sophisticated statistical techniques such as propensity score matching, instrumental variable analysis, and sensitivity analyses should be employed to control for potential confounding factors and minimize bias [2,3].

The passage highlights the potential utility of biomarkers in various stages of bladder cancer management, including early detection, diagnosis, staging, prognosis, and treatment. Biomarkers are measurable indicators that can provide valuable information about disease status and response to treatment. While biomarkers hold promise for improving bladder cancer management, only a few novel biomarkers are currently being used in clinical practice. The reasons for this disparity can be attributed to the challenges and complexities involved in the biomarker development process. To address these challenges and promote the successful translation of biomarkers into clinical use, there is a need for collaborative efforts involving researchers, clinicians, regulatory agencies, and industry partners. Standardization of study protocols, data sharing, and collaboration across institutions can facilitate the validation and replication of biomarker findings. Additionally, investing in infrastructure and resources dedicated to biomarker development can accelerate progress in this field.

Address for Correspondence: Behoz Shang, Department of Biometrics, University of Texas, Texas, USA, E-mail: shang78@edu.in

Copyright: © 2023 Shang B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 27 May, 2023, Manuscript No. Jbms-23-108328; **Editor assigned:** 29 May, 2023, Pre QC No. P-108328; **Reviewed:** 12 June, 2023, QC No. Q-108328; **Revised:** 17 June, 2023, Manuscript No. R-108328; **Published:** 26 June, 2023, DOI: 10.37421/2155-6180.2023.14.168

Defining clinically relevant and meaningful endpoints is critical in real-world data analysis. For regulatory purposes, endpoints should align with established clinical outcomes and be well-defined to allow for consistent evaluation and comparison. Adequate sample size and statistical power are necessary to draw reliable conclusions from real-world data. Statistical power calculations should be performed to ensure that the study has enough participants to detect meaningful effects, if present. Airports, stadiums, and entertainment venues implement biometric access control to manage entry, enhance security, and streamline crowd management validating findings from real-world data studies through independent replication is essential to establish the robustness and generalizability of the results. Implementers must adopt stringent data protection measures, including secure storage, encryption, and compliance with privacy regulations. System accuracy and reliability are crucial to avoid false acceptances or rejections. Understanding the strengths and limitations of real-world data compared to data from clinical trials is important. Real-world data can provide insights into long-term safety and effectiveness, but it may lack the experimental rigor and randomization found in controlled clinical trials [4,5].

Conclusion

Overall, rigorous statistical approaches are essential for utilizing fit-for-use real-world data in drug development to inform regulatory decision making. Careful consideration of data quality, study design, analysis methods, and validation can enhance the reliability and relevance of real-world evidence in the regulatory process and ultimately contribute to improved patient outcomes and public health. Additionally, the integration of block chain technology offers enhanced data security and tamper-proof auditing capabilities. As biometric access control systems continue to advance, we can expect increased accuracy, faster processing times, and broader application possibilities.

Acknowledgement

We thank the anonymous reviewers for their constructive criticisms of the manuscript. The support from ROMA (Research Optimization and recovery in the Manufacturing industry), of the Research Council of Norway is highly appreciated by the authors.

Conflict of Interest

The Author declares there is no conflict of interest associated with this manuscript.

References

1. Li, Ning and William Wang. "Practical and statistical considerations on simultaneous global drug development." *J Biopharm Stat* 22 (2012): 1074-1077.
2. Lee, Kim May, Louise C. Brown, Thomas Jaki and Nigel Stallard, et al. "Statistical consideration when adding new arms to on-going clinical trials: The potentials and the caveats." *Trials* 22 (2021): 1-10.
3. Lachin, John M. "Statistical considerations in the intent-to-treat principle." *CCT* 21 (2000):167-189.
4. Shariat, Shahrokh F., Yair Lotan, Andrew Vickers and Pierre I. Karakiewicz,

- "Statistical consideration for clinical biomarker research in bladder cancer." *Elsevier* 28 (2010): 28389-400
5. Hady, Anar A., Ali Ghubaish, Tara Salman and Devrim Unal, et al. "Intrusion detection system for healthcare systems using medical and network data: A comparison study." *IEEE Access* 8 (2020):106576-106584.

How to cite this article: Shang, Behoz. "Statistical Considerations for Utilizing Fit-for-Use Real-World Data in Drug Development to Inform Regulatory Decision Making." *J Biom Biosta* 14 (2023): 168.